𝔖 Bobbio Scriptorium
✦   LIBER   ✦

5001 ORAL Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study

✍ Scribed by Parsons, S.; Kutarska, E.; Koralewski, P.; Gore, M.; Wimberger, P.; Burges, A.; Sroehlein, M.A.; Friccius-Quecke, H.; Jaeger, M.; Heiss, M.M.

Book ID
122705616
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
60 KB
Volume
5
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The trifunctional antibody catumaxomab f
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
✍ Markus M. Heiss; Pawel Murawa; Piotr Koralewski; Elzbieta Kutarska; Olena O. Kol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 559 KB

## Abstract Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited. The trifunctional antibody catumaxomab (anti‐epithelial cell‐adhesion molecule x anti‐CD3) represents a targeted immunotherapy for the intraperitoneal (i.p.) treatment of malignant ascite